Pacific Edge Ltd

AU:PEB Australia Diagnostics & Research
Market Cap
$104.45 Million
AU$168.68 Million AUD
Market Cap Rank
#18707 Global
#298 in Australia
Share Price
AU$0.17
Change (1 day)
+3.13%
52-Week Range
AU$0.07 - AU$0.22
All Time High
AU$1.54
Categories
Companies in Australia Diagnostics & Research
About

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic produc… Read more

Pacific Edge Ltd - Asset Resilience Ratio

Latest as of September 2025: 20.20%

Pacific Edge Ltd (PEB) has an Asset Resilience Ratio of 20.20% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
AU$6.94 Million
Cash + Short-term Investments
Total Assets
AU$34.38 Million
All company assets
Resilience Assessment
Good
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Pacific Edge Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Pacific Edge Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$6.94 Million 20.2%
Total Liquid Assets AU$6.94 Million 20.20%

Asset Resilience Insights

  • Good Liquidity Position: Pacific Edge Ltd maintains a healthy 20.20% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Pacific Edge Ltd Industry Peers by Asset Resilience Ratio

Compare Pacific Edge Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ADCNF
OTCGREY:ADCNF 		Diagnostics & Research 1.12%
Berry Genomics Co Ltd
SHE:000710 		Diagnostics & Research 0.45%
NSN Co. Ltd
KQ:031860 		Diagnostics & Research 1.72%
JOONGANG DNM Co.Ltd
KQ:051980 		Diagnostics & Research 27.26%
GeneMatrix Inc
KQ:109820 		Diagnostics & Research 41.52%
Genoray Co. Ltd
KQ:122310 		Diagnostics & Research 0.03%
Green Cross Lab Cell Corporation
KQ:144510 		Diagnostics & Research 0.18%
Optipharm.CO.LTD
KQ:153710 		Diagnostics & Research 20.73%

Annual Asset Resilience Ratio for Pacific Edge Ltd (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Pacific Edge Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 35.34% AU$13.09 Million AU$37.03 Million +5.91pp
2024-03-31 29.43% AU$21.00 Million AU$71.35 Million -16.45pp
2023-03-31 45.88% AU$44.56 Million AU$97.12 Million -10.56pp
2022-03-31 56.44% AU$70.00 Million AU$124.03 Million -4.49pp
2021-03-31 60.93% AU$19.00 Million AU$31.18 Million -6.48pp
2020-03-31 67.41% AU$13.03 Million AU$19.33 Million +19.12pp
2019-03-31 48.29% AU$8.00 Million AU$16.57 Million -7.65pp
2018-03-31 55.94% AU$11.00 Million AU$19.66 Million +21.99pp
2017-03-31 33.95% AU$8.00 Million AU$23.56 Million -27.91pp
2016-03-31 61.86% AU$20.00 Million AU$32.33 Million +22.28pp
2015-03-31 39.58% AU$5.00 Million AU$12.63 Million -28.61pp
2014-03-31 68.19% AU$15.50 Million AU$22.73 Million +33.87pp
2013-03-31 34.32% AU$4.20 Million AU$12.22 Million --
pp = percentage points